Cadila Launches Empadon to Revolutionize Diabetes and Heart Disease Care in India

Ahmedabad, Gujarat – Cadila Pharmaceuticals, a pioneer in affordable and innovative healthcare solutions, proudly announces the launch of Empadon (Empagliflozin), marking its strategic foray into the transformative SGLT2 inhibitor therapy space. This launch reinforces the company’s unwavering commitment to redefining chronic disease management in India with high quality, affordable solutions.

The SGLT2 inhibitor class, with Empagliflozin at its forefront, has emerged as a cornerstone in the management of Type 2 Diabetes Mellitus (T2DM), Cardiovascular Disease (CVD), and Chronic Kidney Disease (CKD). With the recent expiry of Empagliflozin’s patent, the landscape is ripe for expanding access to this game-changing therapy.

Empadon enters a rapidly growing ₹611 crore market, previously dominated by just five players. Post-patent expiry, more than 40 players are expected to enter the segment. In this competitive environment, Cadila Pharmaceuticals is leading the way by offering Empadon at nearly one-fourth the cost of the innovator brand, making it more accessible to millions of Indian patients.

“With Empadon, we reaffirm our mission to make global-standard therapies within reach of every Indian,” said a spokesperson from Cadila Pharmaceuticals. “Our entry into the SGLT2 market reflects our scientific excellence and deep-rooted ethos of affordability.”

Empadon’s benefits extend far beyond glycaemic control. Clinical trials, including EMPA-REG OUTCOME and EMPEROR-Preserved, have consistently shown empagliflozin’s efficacy in reducing cardiovascular mortality, heart failure hospitalizations, and slowing the progression of kidney disease. It offers early and sustained risk reduction in patients with established atherosclerotic cardiovascular disease, heart failure (across HFrEF, HFmrEF, HFpEF), and CKD—even at early stages.

Empadon will also be available in fixed-dose combinations with other oral antidiabetic agents, enabling personalized therapy as per national and international diabetes management guidelines. Its beta-cell independent mechanism, favourable safety profile, and multiple metabolic benefits — including weight loss, improved insulin sensitivity and lower risk of hypoglycaemia — make it a holistic option for long-term disease control.

With Empadon, Cadila Pharmaceuticals continues to empower physicians and patients with cutting-edge therapeutics that offer real-world benefits beyond sugar control—shaping a future where diabetes, heart failure, and CKD are managed proactively and efficiently.